# US 2012/0251585 A1 · Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251585 A1
- Document ID: US20120251585A1
- Status: Published application
- Kind: A1
- Application number: 13/245,705
- Filed: 2011-09-26
- Published: 2012-10-04
- Earliest claimed: 2000-12-27
- Assignees: Gilead Sciences, Inc.
- Inventors: Alan Bruce Montgomery
- Web page: https://patentgrep.com/patent/US20120251585A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61P 31/04: Antibacterial agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.

## Claims

### Claim 1

A method of treating pulmonary infections caused by gram-negative bacteria, said method comprising delivering an aerosol of an inhalable aztreonam lysinate formulation to the lung endobronchial space of airways of a patient in need thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein said inhalable aztreonam lysinate formulation comprises from about 1 to about 250 mg of aztreonam lysinate per one dose.

### Claim 3 (depends on 2)

The method of claim 2 wherein said aerosol comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 ml of a saline solution containing from about 0.1 to about 0.9% of sodium chloride or an equivalent thereof.

### Claim 4 (depends on 3)

The method of claim 3 wherein said aerosol is nebulized into particles, at least 70% of which have sizes between about 1 and about 5 μm.

### Claim 5 (depends on 4)

The method of claim 4 wherein the inhalable aztreonam lysinate formulation is delivered one to twelve times a day, provided that a total dose of aztreonam lysinate is not higher than 750 mg a day.

### Claim 6 (depends on 5)

The method of claim 5 wherein said aerosol is delivered by a nebulizer.

### Claim 7 (depends on 6)

The method of claim 6 wherein the nebulizer is an atomizing nebulizer or a jet, ultrasonic, electronic or vibrating porous plate nebulizer, wherein said nebulizer is able to or is modified to be able to nebulize volume from about 1 to about 5 ml of the inhalable aztreonam lysinate formulation to particle, the sizes of which range from about 1 to about 5 μm.

### Claim 8 (depends on 7)

The method of claim 7 wherein the inhalable aztreonam lysinate formulation comprises from about 10 to about 200 mg of the aztreonam lysinate.

### Claim 9 (depends on 8)

The method of claim 8 wherein the inhalable aztreonam lysinate formulation comprises from about 50 to about 150 mg of aztreonam lysinate.

### Claim 10 (depends on 9)

The method of claim 9 wherein the aerosol has pH from about 4.5 to about 7.5 and the saline solution contains from about 0.1 to about 0.45% of sodium chloride.

### Claim 11 (depends on 10)

The method of claim 10 wherein said aerosol has pH from about 4.5 to about 5.5.

### Claim 12 (depends on 11)

The method of claim 11 wherein said aztreonam lysinate is derived from alpha form of aztreonam.

### Claim 13 (depends on 3)

The method of claim 3 comprising administering the aerosol comprising from about 10 to about 150 mg of the aztreonam lysinate once, twice, three or four times a day.

### Claim 14 (depends on 13)

The method of claim 13 wherein said aerosol comprises about 75 mg of aztreonam per 1 ml of saline.

### Claim 15 (depends on 14)

The method of claim 14 wherein the aztreonam lysinate is derived from alpha form of aztreonam.

### Claim 16 (depends on 15)

The method of claim 15 wherein said aztreonam lysinate has impurity lower than 1% and stability for at least two years.

### Claim 17 (depends on 16)

The method of claim 16 wherein said aztreonam lysinate contains less than 100 ppm of residual alcohol and initial levels of contaminants generated from the alpha form of aztreonam are less than 1%.

### Claim 18

A method of treating infections caused by the gram-negative bacteria in patients with cystic fibrosis or bronchiectasis, or in patients on ventilators with pneumonia, comprising delivering an aerosol of an inhalable aztreonam lysinate formulation to the lung endobronchial space of airways of a patient in need thereof, wherein the inhalable aztreonam lysinate formulation comprises from about 1 to about 250 mg of aztreonam lysinate.

### Claim 19 (depends on 18)

The method of claim 18 wherein said aztreonam lysinate is derived from alpha form of aztreonam.

### Claim 20

A method of treating pulmonary infections caused by gram-negative bacteria comprising delivering an aerosol of an inhalable aztreonam lysinate formulation to the lung endobronchial space of airways of a patient in need thereof, wherein the inhalable aztreonam formulation comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 ml of a saline solution.

### Claim 21 (depends on 20)

The method of claim 20 wherein said inhalable aztreonam lysinate formulation comprises about 75 mg of aztreonam dissolved in about 1 ml of saline solution.

### Claim 22 (depends on 21)

The method of claim 21 wherein said aztreonam lysinate is derived from alpha form of aztreonam.

### Claim 23 (depends on 22)

The method of claims 22 wherein said gram-negative bacteria is Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Serratia marcescens, Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans or multidrug resistant Pseudomonas aeruginosa.

### Claim 24

An inhalable pharmaceutically acceptable composition comprising from about 1 to about 250 mg per one dose of aztreonam lysinate, said composition suitable for treatment of pulmonary bacterial infections caused by gram-negative bacteria wherein said aztreonam lysinate is prepared as an aerosolable saline solution.

### Claim 25 (depends on 24)

The composition of claim 24 administered once, two, three or four times a day with a proviso that when the composition is administered more than three times a day, the total dose of the aztreonam lysinate does not exceed 750 mg a day.

### Claim 26 (depends on 25)

The composition of claim 25 wherein said aztreonam lysinate is dissolved in from about 1 to about 5 ml of the aerosolable saline solution comprising at least 0.09% of sodium chloride or equivalent amount of bromine, iodine or bicarbonate salt.

### Claim 27 (depends on 26)

The composition of claim 26 wherein said aerosolable saline solution comprises from about 0.1 to about 0.45% of sodium chloride and has pH from about 4.5 to about 7.5.

### Claim 28 (depends on 27)

The composition of claim 27 wherein said aerosolable saline solution has pH from about 4.5 to about 5.5.

### Claim 29 (depends on 28)

The composition of claim 28 nebulized into particles, at least 70% of which have sizes between about 1 and about 5 μm.

### Claim 30 (depends on 29)

The composition of claim 29 comprising about 75 mg of aztreonam dissolved in about 1 ml of saline.

### Claim 31 (depends on 30)

The composition of claim 30 wherein said aztreonam lysinate is derived from alpha form of aztreonam.

### Claim 32 (depends on 31)

The composition of claim 31 wherein said aztreonam lysinate has impurity lower than 1% and stability for at least two years.

### Claim 33 (depends on 32)

The composition of claim 32 wherein said aztreonam lysinate contains less than 100 ppm of residual alcohol and initial levels of contaminants generated from the alpha form of aztreonam are less than 1%.

### Claim 34

An aerosol composition comprising from about 1 to about 250 mg of aztreonam lysinate, wherein said aztreonam lysinate is dissolved in from about 1 to about 5 ml of a saline solution containing from about 0.1 to about 0.9% sodium chloride.

### Claim 35 (depends on 34)

The aerosol of claim 34 comprising about 75 mg of aztreonam lysinate per 1 ml of saline solution.

### Claim 36 (depends on 35)

The aerosol of claim 35 wherein said aztreonam lysinate is derived from alpha form of aztreonam.
